We've found
2,815
archived clinical trials in
Parkinsons Disease
We've found
2,815
archived clinical trials in
Parkinsons Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Updated: 1/1/1970
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Parkinson's Disease Isradipine Safety Study
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
Parkinson's Disease Isradipine Safety Study
Updated: 1/1/1970
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
Updated: 1/1/1970
Early Parkinson's Disease (PD) Cross-Sectional
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
Early Parkinson's Disease (PD) Cross-Sectional
Updated: 1/1/1970
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
Updated: 1/1/1970
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Updated: 1/1/1970
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Updated: 1/1/1970
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
Updated: 1/1/1970
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Updated: 1/1/1970
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Updated: 1/1/1970
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Updated: 1/1/1970
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970